Based on the Capricor Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Capricor Therapeutics Inc is USD 38.63 over the next 12 months. Capricor Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Capricor Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Capricor Therapeutics Inc’s stock price was USD 9.40. Capricor Therapeutics Inc’s stock price has changed by -3.49% over the past week, -26.62% over the past month and +49.21% over the last year.
No recent analyst target price found for Capricor Therapeutics Inc
No recent average analyst rating found for Capricor Therapeutics Inc
Company Overview Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California. Read Less
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, ...Read More
Frequently Asked Questions About Capricor Therapeutics Inc (CAPR) Stock
Based on ratings from 5 analysts Capricor Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on CAPR's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for CAPR is USD 38.63 over the next 12 months. The maximum analyst target price is USD 43 while the minimum anlayst target price is USD 30.
CAPR stock's Price/Earning ratio is 4.20.
Our analysis grades CAPR stock's Price / Earning ratio at F. This means that CAPR stock's Price/Earning ratio is above 46% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CAPR may be fairly valued for its sector
The last closing price of CAPR's stock was USD 9.40.
The most recent market capitalization for CAPR is USD 0.65B.
Based on targets from 5 analysts, the average taret price for CAPR is projected at USD 38.63 over the next 12 months.
This means that CAPR's stock price may go up by +310.90% over the next 12 months.
We can't find any ETFs which contains Capricor Therapeutics Inc's stock.
As per our most recent records Capricor Therapeutics Inc has 0 Employees.
Capricor Therapeutics Inc's registered address is 10865 Road to the Cure, San Diego, CA, United States, 92121.
You can get more information about it from Capricor Therapeutics Inc's website at https://www.capricor.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Capricor Therapeutics Inc (CAPR) Stock
Based on ratings from 5 analysts Capricor Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on CAPR's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for CAPR is USD 38.63 over the next 12 months. The maximum analyst target price is USD 43 while the minimum anlayst target price is USD 30.
CAPR stock's Price/Earning ratio is 4.20.
Our analysis grades CAPR stock's Price / Earning ratio at F. This means that CAPR stock's Price/Earning ratio is above 46% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CAPR may be fairly valued for its sector
The last closing price of CAPR's stock was USD 9.40.
The most recent market capitalization for CAPR is USD 0.65B.
Based on targets from 5 analysts, the average taret price for CAPR is projected at USD 38.63 over the next 12 months.
This means that CAPR's stock price may go up by +310.90% over the next 12 months.
We can't find any ETFs which contains Capricor Therapeutics Inc's stock.
As per our most recent records Capricor Therapeutics Inc has 0 Employees.
Capricor Therapeutics Inc's registered address is 10865 Road to the Cure, San Diego, CA, United States, 92121.
You can get more information about it from Capricor Therapeutics Inc's website at https://www.capricor.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CAPR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
